EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study

Tatsuro Murano iD, Hiroaki Ikematsu iD, Nobuhisa Matsuhashi, Yuichiro Tsukada iD, Manabu Shiozawa, Takeshi Kato iD, Eiji Oki iD, Toshifumi Yamaguchi iD, Yoshinori Kagawa iD, Akiyoshi Kanazawa, Takashi Ohta iD, Akira Ouchi iD und 9 weitere

JCO Precision Oncology · 2026-07 · 10 (7)

DOI: 10.1200/po-25-00941 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Tatsuro Murano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Colorectal Neoplasms, Early Detection of Cancer, Lymphatic Metastasis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Shield test is a blood-based assay that uses multimodal analysis of cell-free DNA (cfDNA) to enable noninvasive colorectal cancer (CRC) detection. The aim of this study was to assess the diagnostic performance of the cfDNA test for CRC and advanced precancerous lesions (APLs) and evaluate its potential clinical utility, particularly in early-stage disease. METHODS In this prospective, multicenter study, 451 patients with histologically confirmed CRC or APLs were enrolled across eight institutions. Blood samples collected before treatment were analyzed using the cfDNA test (Shield, Guardant Health, United States). We assessed the sensitivity of the test for different CRC stages and APLs. In addition, we examined the correlation between test positivity and clinicopathologic factors in stage I and T1 CRC. RESULTS The test showed 87.9% sensitivity for CRC overall, with stage-specific sensitivities of 71.2% for stage I and 97.4% for stages II-IV. Sensitivity for APLs was 37.0%. In stage I CRC, test positivity was significantly associated with tumor depth (T2: 88.6% v T1: 59.7%, P < .01). Among 70 patients with T1 CRC, the test detected all to have lymph node metastasis (LNM; 100% sensitivity). Compared with guideline-based pathologic criteria, the cfDNA test achieved higher specificity for LNM prediction (38.7% v 11.3%), thereby potentially reducing the frequency of unnecessary radical surgery from 78.6% to 54.3%. CONCLUSION This cfDNA blood-based test shows a robust diagnostic performance in CRC detection. It may improve risk stratification and support more tailored clinical decision making, particularly in the management of T1 CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsColorectal NeoplasmsEarly Detection of CancerLymphatic MetastasisAgedFemaleHumansMaleMiddle AgedNeoplasm StagingProspective StudiesSensitivity and Specificity

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Gastroenterological Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Surgery, NHO Osaka National Hospital, Osaka, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Tatsuro Murano, Hiroaki Ikematsu, Yuichiro Tsukada, Takeshi Kato, Eiji Oki, Toshifumi Yamaguchi, Yoshinori Kagawa, Takashi Ohta, Akira Ouchi, Victoria M Raymond, Hideaki Bando, Takayuki Yoshino, Yoshiaki Nakamura

Zitieren

APA

Murano, T., Ikematsu, H., Matsuhashi, N., Tsukada, Y., Shiozawa, M., Kato, T., Oki, E., Yamaguchi, T., Kagawa, Y., Kanazawa, A., Ohta, T., Ouchi, A., Uchigata, H., Notake, C., Forouzmand, E., He, Y., Raymond, V. M., Duenwald, S., Bando, H., …, & Nakamura, Y. (2026). Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-00941

Vancouver

Murano T, Ikematsu H, Matsuhashi N, Tsukada Y, Shiozawa M, Kato T, et al. Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-00941

BibTeX
@article{Murano2026,
  author = {Murano, Tatsuro and Ikematsu, Hiroaki and Matsuhashi, Nobuhisa and Tsukada, Yuichiro and Shiozawa, Manabu and Kato, Takeshi and Oki, Eiji and Yamaguchi, Toshifumi and Kagawa, Yoshinori and Kanazawa, Akiyoshi and Ohta, Takashi and Ouchi, Akira and Uchigata, Hiroshi and Notake, Chiemi and Forouzmand, Elmira and He, Yupeng and Raymond, Victoria M and Duenwald, Sven and Bando, Hideaki and Yoshino, Takayuki and Nakamura, Yoshiaki},
  title = {Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {7},
  doi = {10.1200/po-25-00941}
}
Kostenlos starten →